Our technology gives failed drug molecules a second chance.

Construction of Nanoform’s GMP manufacturing plant rapidly progresses

PRESS RELEASE 05 March 2019 Construction of Nanoform’s GMP manufacturing plant rapidly progresses Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced significant progress in the construction of its new 600m2 GMP manufacturing plant, located at Cultivator II in Viikki Life Science Park, Finland. These important advancements in the project will enable …

Construction of Nanoform’s GMP manufacturing plant rapidly progressesRead More »

28.01.2019 Nanoform signs world-leading sparse data AI expert

PRESS RELEASE 28 January 2019 Nanoform signs world-leading sparse data AI expert Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced the appointment of Prof Jukka Corander as Head of AI. Prof Corander will be working closely with Nanoform to apply sparse data AI to enhance Nanoform’s proprietary STARMAP™ nanonization™ technology. Prof …

28.01.2019 Nanoform signs world-leading sparse data AI expertRead More »

14.01.2019 Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer

PRESS RELEASE 14 January 2019 Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Niklas Sandler as Chief Technology Officer. The role will combine significant pharmaceutical R&D knowledge with commercial expertise to develop the technological resources required for …

14.01.2019 Nanoform set to boost world-class nanonization services with appointment of Chief Technology OfficerRead More »

07.01.2019 Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment

PRESS RELEASE 7 January 2019 Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr Gonçalo Rebelo de Andrade as Chief of Business Operations. The newly created role will significantly strengthen Nanoform’s commercial organisation and continue its rapid growth through international …

07.01.2019 Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointmentRead More »

10.12.2018 Nanoform continues rapid expansion with construction of GMP manufacturing plant

PRESS RELEASE 10 December 2018 Nanoform continues rapid expansion with construction of GMP manufacturing plant Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has announced the construction of a GMP manufacturing plant to provide API ‘solution to particle’ nanonization for clinical trials. A nine-year contract has been signed to build the 600m2 facility …

10.12.2018 Nanoform continues rapid expansion with construction of GMP manufacturing plantRead More »

29.10.2018 Nanoform set to globalize its technology with appointment of a Chief Commercial Officer

PRESS RELEASE 29 October 2018 Nanoform set to globalize its technology with appointment of a Chief Commercial Officer Helsinki, Finland – Nanoform, a Helsinki, Finland-based drug particle engineering and nanotechnology company, is set to globalize its novel nanonization technology with the appointment of Christian Jones as Chief Commercial Officer. The newly created role is imperative …

29.10.2018 Nanoform set to globalize its technology with appointment of a Chief Commercial OfficerRead More »

19.09.2018 Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology

PRESS RELEASE 19 September 2018 Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology Helsinki, Finland – Nanoform, an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, is continuing its strategic growth through a significant €7 million investment, with Vator Securities acting as the …

19.09.2018 Nanoform set to transform drug development through €7 million investment in patented nanoparticle technologyRead More »